English
Back
Download
Log in to access Online Inquiry
Back to the Top

Biopharmaceutical Company Partners With Novavax: COVID-19 Vaccine Co-commercialization

The financial terms of the deal are robust, with Novavax receiving an upfront payment of $500 million from Sanofi.
In the fight against COVID-19 and influenza, Sanofi and Novavax Inc. have announced a landmark co-exclusive licensing agreement. This massive partnership marks a pivotal step forward in addressing ongoing public health needs by co-commercializing COVID-19 vaccines and developing innovative COVID-19-Influenza combination vaccines, which could redefine seasonal vaccination strategies moving forward. $Amesite (AMST.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
4884 Views
Comment
Sign in to post a comment
    253
    Followers
    0
    Following
    536
    Visitors
    Follow
    Discussing
    Trump 2.0 Era: How will global markets evolve?
    🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More